Celgene to Acquire Juno for its Cellular Immunotherapy & Hematology Portfolio

 Celgene to Acquire Juno for its Cellular Immunotherapy & Hematology Portfolio

Celgene Licenses Aprinoia’s APN-1607 an Imaging Tracer, for Neurodegenerative Diseases

Shots:

  • Celgene acquires Juno, in all stock transaction with its JCAR017& JCARH125 clinical products. Juno to receive $87/share in cash, making total deal value as $9B
  • The focus of the agreement is to develop drugs in fields of oncology and hematology with Juno’s cellular immunotherapy platform and research capabilities
  • JCAR017 (lisocabtagene maraleucel; liso-cel) is a CD19-directed CAR T therapy, targeted for r/r diffuse large B-cell lymphoma (DLBCL) with its expected approval in 2019 by the US FDA. JCARH125 is an anti BCMA (B-cell maturation antigen) therapy, evaluated in P-I/II for r/r Multiple Myeloma
     

Click here to read full press release/ article | Ref: Celgene| Image: The Street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post